9AA Limited Human
DSIP
Endogenous nonapeptide isolated from sleeping rabbit brain that promotes delta-wave sleep architecture and has stress-protective, neuroprotective, and withdrawal-attenuating effects across 543 PubMed publications.
In Plain English:
DSIP is a tiny 9-amino-acid peptide your body makes naturally and which was first extracted in 1974 from the blood of rabbits during deep slow-wave sleep. Injecting it before bed appears to deepen the most restorative phase of sleep — the delta-wave stage — without causing next-day grogginess at lower doses. Beyond sleep, animal studies suggest it protects against oxidative stress, seizures, and the severity of drug and alcohol withdrawal, and a 2021 rodent study found it accelerated motor recovery after stroke. Human evidence is real but thin: the strongest trial (14 chronic insomniacs, 1987) showed meaningful improvement in both night sleep and daytime alertness, while a stricter 1992 trial (16 subjects) found only modest objective gains. The peptide degrades in blood within 7–15 minutes, yet its effects last multiple nights — pointing to downstream gene and signalling cascades rather than sustained plasma presence.
Research Maturity
Limited Human (543 PubMed publications; 2+ double-blind human RCTs, 1 withdrawal trial (n=71); no phase III trials+ Studies)
Focus
Neuroendocrine Modulation
Sleep
Stress Response
Origin
First isolated in 1974 by Marcel Monnier and colleagues at the University of Basel from the cerebral venous blood of rabbits induced into slow-wave sleep. The nonapeptide was sequenced as Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and confirmed synthetically. DSIP-like immunoreactivity subsequently found in rat brain, pituitary, peripheral organs, and human breast milk, suggesting endogenous biosynthesis beyond its original isolation context.
Mechanism
Multi-pathway: (1) modulates NMDA glutamate receptors to dampen excitatory tone; (2) potentiates GABAergic transmission; (3) suppresses HPA axis — reduces baseline ACTH and cortisol, blunting stress-driven arousal; (4) inhibits somatostatin release via dopaminergic mechanism, disinhibiting growth hormone pulses; (5) stimulates acetyltransferase via α1-adrenoreceptors; (6) interacts with MAPK cascade; (7) structurally homologous to glucocorticoid-induced leucine zipper (GILZ), explaining broad anti-stress signalling. A 2024 fusion peptide study (DSIP-CBBBP) demonstrated modulation of melatonin, serotonin, dopamine, and glutamate in a PCPA-induced insomnia mouse model, with superior BBB penetration restoring neurotransmitter balance better than native DSIP.
Outcome
EEG delta-wave amplitude and duration (increased in rabbits, rats, mice, and humans); sleep latency (shortened in 1992 RCT); sleep efficiency (improved in two human trials); daytime alertness and mental performance (improved in 1987 n=14 trial); cortisol and ACTH levels (reduced); growth hormone release (augmented); mitochondrial respiratory activity (protected under hypoxia); seizure incidence and duration (reduced in metaphit-induced epilepsy rats); motor function recovery after focal stroke (accelerated in SD rat model, 2021); opioid and alcohol withdrawal severity (reduced in 1984 Schneider trial, n=71).
